Dr. Douglas Jolly was born in the United Kingdom and received a Ph.D in Biochemistry from the University of Glasgow. Before entering the biopharmaceutical industry, Dr. Jolly pursued his academic career in biophysics and molecular biology at the Weizmann Institute, Harvard Medical School, Scripps Clinic, the University of California, San Diego and The French National Institute for Health and Medical Research (INSERM) in Paris, France. For many years Dr. Jolly was a senior biotechnology executive involved in translating gene-based products from research through clinical development at Viagene, Inc., Chiron Corporation, Oxford BioMedica, Inc., and Advantagene, Inc., where he also served as President. Dr. Jolly co-founded Tocagen, and previously co-founded Viagene. He is an internationally recognized expert in the field of gene therapy and its industrial application with over 100 published scientific articles and an inventor on over 45 issued patents. Dr. Jolly has also served as Vice Chairman of the Industrial Liaison Committee of the American Society of Gene Therapy (ASGT).
Interviewed by Mark Jones, PhD
At the time of this interview, Dr. Jolly was the Vice President of Scientific Affairs at Chiron Corporation.